Filing Details
- Accession Number:
- 0001140361-15-044782
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-12-16 17:31:33
- Reporting Period:
- 2015-12-14
- Filing Date:
- 2015-12-16
- Accepted Time:
- 2015-12-16 17:31:33
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1444380 | Nevro Corp | NVRO | Surgical & Medical Instruments & Apparatus (3841) | 562568057 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1622608 | Andre Walker | C/O Nevro Corp. 1800 Bridge Parkway Redwood City CA 94065 | Senior Vp,Research&Development | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2015-12-14 | 3,000 | $1.44 | 3,470 | No | 4 | M | Direct | |
Common Stock | Disposition | 2015-12-14 | 2,000 | $66.58 | 1,470 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-12-14 | 1,000 | $68.00 | 470 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2015-12-14 | 3,000 | $0.00 | 3,000 | $1.44 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
47,422 | 2019-06-30 | No | 4 | M | Direct |
Footnotes
- The sales were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $66.15 to $67.00, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- 100% of the shares subject to the option are fully vested and exercisable.